Corrections to Pediatric ARV Treatment Guidelines
On November 5, 2012, corrections were made to the Pediatric ARV Treatment Guidelines (released November 1, 2012) to correct the following errors:
In What's New in the Guidelines? under What Drugs to Start, the phrase “oral granules” erroneously used to describe raltegravir has been removed.
In the Appendix A record for raltegravir, under Pediatric Use, the GM 12 hr concentration sited has been changed from “13 nM” to “>33 nM.” The statement now correctly reads:
- Dose selection was based upon achieving target PK parameters similar to those seen in adults: PK targets are geometric mean (GM) area under the curve of 14-25 μMxh and GM 12 h concentration >33 nM.
Study Finds HPV Vaccine May Benefit HIV-Infected Women
“Women with HIV may benefit from a vaccine for human papillomavirus (HPV), despite having already been exposed to HPV, a study finds. Although many may have been exposed to less serious forms of HPV, more than 45 percent of sexually active young women who have acquired HIV appear never to have been exposed to the most common high-risk forms of HPV, according to the study from a National Institutes of Health research network. ...
“The researchers noted that earlier studies had found many women with HIV were more likely than were women who did not have HIV to have conditions associated with HPV, such as precancerous conditions of the cervix, as well as for cervical cancer.
“‘Health care providers may hesitate to recommend HPV vaccines after a girl starts having sex,’ said study first author Jessica Kahn, M.D., M.P.H. of Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine. ‘However, our results show that for a significant number of young women, HPV vaccine can still offer benefits. This is especially important in light of their HIV status, which can make them even more vulnerable to HPV's effects.’”
More information is available: